Generic Duobrii Availability

Last updated on Jun 11, 2025.

Duobrii is a brand name of halobetasol/tazarotene topical, approved by the FDA in the following formulation(s):

DUOBRII (halobetasol propionate; tazarotene - lotion;topical)

• Manufacturer: BAUSCH
  Approval date: April 25, 2019
  Strength(s): 0.01%;0.045% ^{[RLD] [AB]}

Is there a generic version of Duobrii available?

A generic version of Duobrii has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Duobrii and have been approved by the FDA:

HALOBETASOL PROPIONATE AND TAZAROTENE (halobetasol propionate; tazarotene lotion;topical)

• Manufacturer: TARO
  Approval date: May 2, 2025
  Strength(s): 0.01%;0.045% ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Duobrii. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Topical compositions and methods for treating psoriasis
  Patent 10,251,895
  Issued: April 9, 2019
  Inventor(s): Dow Gordon J. & Pillai Radhakrishnan & Bhatt Varsha D.
  Assignee(s): Valeant Pharmaceuticals North America
  

  Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same.

  Patent expiration dates:

  • June 6, 2036
    
    ✓ 
    Drug product
• Topical compositions and methods for treating psoriasis
  Patent 10,426,787
  Issued: October 1, 2019
  Inventor(s): Dow Gordon J. & Pillai Radhakrishnan & Bhatt Varsha D.
  Assignee(s): Bausch Health US, LLC
  

  Topical pharmaceutical compositions comprise a combination of a corticosteroid and a retinoid; and methods for treating psoriasis with same. In one embodiment, the corticosteroid comprises halobetasol propionate, and the retinoid comprises tazarotene.

  Patent expiration dates:

  • June 6, 2036
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
• Pharmaceutical formulations containing corticosteroids for topical administration
  Patent 10,478,502
  Issued: November 19, 2019
  Inventor(s): Angel Arturo & Dow Gordon
  Assignee(s): Dow Pharmaceutical Sciences, Inc.
  

  Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.

  Patent expiration dates:

  • November 2, 2031
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
    ✓ 
    Drug product
• Topical compositions and methods for treating psoriasis
  Patent 11,648,256
  Issued: May 16, 2023
  Inventor(s): Dow; Gordon J. et al.
  Assignee(s): Bausch Health Ireland Limited (Dublin, IE)
  

  Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same.

  Patent expiration dates:

  • June 6, 2036
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
    ✓ 
    Drug product
• Topical compositions and methods for treating psoriasis
  Patent 11,679,115
  Issued: June 20, 2023
  Inventor(s): Dow; Gordon J. et al.
  Assignee(s): Bausch Health Ireland Limited (Dublin, IE)
  

  Topical pharmaceutical compositions comprise a combination of a corticosteroid a retinoid; and methods for treating psoriasis with same.

  Patent expiration dates:

  • June 6, 2036
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
    ✓ 
    Drug product
• Pharmaceutical formulations containing corticosteroids for topical administration
  Patent 11,839,656
  Issued: December 12, 2023
  Inventor(s): Angel; Arturo et al.
  Assignee(s): Bausch Health Ireland Limited (Dublin, IE)
  

  Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.

  Patent expiration dates:

  • November 2, 2031
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
• Pharmaceutical formulations containing corticosteroids for topical administration
  Patent 11,957,753
  Issued: April 16, 2024
  Inventor(s): Angel; Arturo et al.
  Assignee(s): BAUSCH HEALTH IRELAND LIMITED (Dublin, IE)
  

  Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.

  Patent expiration dates:

  • November 2, 2031
    
    ✓ 
    Drug product
• Pharmaceutical formulations containing corticosteroids for topical administration
  Patent 11,986,527
  Issued: May 21, 2024
  Inventor(s): Angel; Arturo et al.
  Assignee(s): BAUSCH HEALTH IRELAND LIMITED (Dublin, IE)
  

  Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.

  Patent expiration dates:

  • November 2, 2031
    
    ✓ 
    Patent use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
• Pharmaceutical formulations containing corticosteroids for topical administration
  Patent 12,076,403
  Issued: September 3, 2024
  Inventor(s): Angel; Arturo et al.
  Assignee(s): Bausch Health Ireland Limited (Dublin, IE)
  

  Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.

  Patent expiration dates:

  • November 2, 2031
    
    ✓ 
    Drug product
• Pharmaceutical formulations containing corticosteroids for topical administration
  Patent 8,809,307
  Issued: August 19, 2014
  Inventor(s): Angel Arturo & Dow Gordon
  Assignee(s): Dow Pharmaceutical Sciences, Inc.
  

  The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.

  Patent expiration dates:

  • November 2, 2031
    
    ✓ 
    Drug product

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer